Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$9MCash on Hand
33.2mo Cash Runway
Follow IMRN by emailGet an email when IMRN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IMRN, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Deal Immuron has engaged LifeSci Capital as its exclusive financial advisor to evaluate strategic initiatives that may include mergers, acquisitions, licensing or other transactions. Form 6-K · SEC filing · Press release
Oct 28, 2026 ·
Immuron furnished an October 28, 2026 ASX announcement that CEO Steven Lydeamore will present at the Emerging Growth Conference in Melbourne, 4:25pm to 4:55pm U.S. Eastern Time. The filing includes general background on its Travelan, IMM-529 and ProIBS programs but no new data. Form 6-K · SEC filing · Press release
Oct 27, 2026 ·
Earnings Unaudited FY27 Q1 sales (quarter ending Sept 30, 2026) were AUD$2.2 million, up 9% on the prior comparative period. Australia rose 14% to AUD$1.8 million, Canada rose 286% to AUD$0.1 million, and USA fell 19% to AUD$0.3 million. Form 6-K · SEC filing · Press release
Oct 23, 2026 ·
Financing Immuron is offering up to $2,006,769 of American Depositary Shares through H.C. Wainwright & Co. under an at-the-market agreement, with a 3.0% cash commission. The amount reflects a reduced limit under SEC Form F-3 baby shelf rules, and the ADS closed at $0.97 on October 22, 2026. Form 424B5 · SEC filing
Oct 23, 2026 ·
Financing Immuron decreased the amount available under its at-the-market offering agreement with H.C. Wainwright & Co. to an aggregate offering price of $2,006,769, excluding $2,847,703 of securities sold under General Instruction I.B.5 of Form F-3 in the prior 12 months. Form 6-K · SEC filing
Oct 22, 2026 ·
CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on October 28, 2026, from 4:25pm to 4:55pm U.S. Eastern Time. Investors can submit questions in advance or during the event. Form 6-K · SEC filing · Press release
Oct 13, 2026 ·
Clinical trial Immuron published Phase 2 Travelan results in Scientific Reports, showing a 50% reduction in ETEC challenge-related adverse events versus placebo (P=0.0001). The primary efficacy endpoints were not met due to a lower placebo attack rate (33% versus 70%). Form 6-K · SEC filing · Press release
Sep 24, 2026 ·
Immuron Limited furnished a 6-K attaching its ASX Appendix 4G and Corporate Governance Statement for the financial year ended 30 June 2026, dated 24 September 2026. The Appendix 4G serves as a key to where governance disclosures can be found. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jul 2024 · Phase 2 · Results Expected · Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model. Registry primary completion date, not a results date
Oct 2017 · Phase 2 · Results Expected · A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
IMRN holds $9M in cash and short-term investments and burns about $814,930/quarter from operations,
an estimated runway of 33.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:14 · Low
Cash runway 33 months
Shelf registration (F-3, Jul 2024) +10
Share count +38% in a year +14
Raised after last reported balance sheet (Oct 2026) -10
Share count 322,848,081 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full IMRN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMRN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.